Bausch + Lomb

What Bausch + Lomb does

Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health company founded in 1853 and headquartered in Vaughan, Canada, operating as a subsidiary of Bausch Health Companies Inc. It is structured across four revenue streams: surgical devices and instruments (cataract, retinal, refractive, and corneal), intraocular lenses (monofocal, toric, and premium presbyopia-correcting), contact lenses and lens care products (including Biotrue, which holds a 55–65% brand value share in the Brazil contact-lens solution market alongside Alcon), ophthalmic pharmaceuticals (expanded materially with the 2024 acquisition of Xiidra from Novartis for $2.5 billion), and consumer eye health (PreserVision AREDS vitamins and OTC products). The Surgical franchise is anchored on the Stellaris Elite Vision Enhancement System, a combined cataract and retina surgical platform featuring Bi-Blade+ dual-port vitrectomy cutters (25,000 cuts per minute), Adaptive Fluidics dynamic infusion compensation, the VICTUS femtosecond laser, the TECHNOLAS TENEO excimer laser, and the ANTERION swept-source OCT diagnostic platform; intraocular lens offerings span the enVista, LuxSmart, LuxGood, LuxLife, EyeCee, Akreos, and IC-8 families, with enVista Envy (the first Bausch + Lomb diffractive premium IOL in Europe) and LuxSmart (Pure Refractive Optics) as key premium platforms.

The company operates an enterprise B2B go-to-market via direct field-sales representatives, regional sales offices, and exclusive distribution partners across approximately 100 countries, with dedicated sales/customer-service infrastructure in 18+ EMEA markets. Products are sold to ophthalmic surgeons, hospitals, ambulatory surgery centers, and eye care professionals; consumer products move through retail, pharmacy, and e-commerce channels. Manufacturing is anchored by a 1.1 million-square-foot Rochester, NY campus producing hundreds of millions of contact lenses annually (with a complementary Waterford, Ireland facility for next-generation lenses), a Heidelberg Instruments Centre of Excellence for Storz ophthalmic instruments, and Italian ophthalmic manufacturing. The pipeline includes the ELIOS implant-free excimer-laser MIGS device for glaucoma (anticipating 2026 regulatory approval), BL 1107 neuroprotective glaucoma therapy in Phase II, a polymerized hyaluronic acid bioactive contact lens, a myopia-control silicone-hydrogel daily disposable, and an RNAi retinal program partnered with City Therapeutics (up to $485 million). Q4 2025 revenue was $1.41 billion, up 9.8% year on year, and the company completed an approximately $3 billion refinancing in June 2025 (€675 million senior secured notes plus a $2.325 billion term loan and $800 million revolver).

Name

Bausch + Lomb

Legal name

Bausch + Lomb Corporation

Website

https://bauschsurgical.eu

Company type

Public

Founded year

1853

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Bausch + Lomb is a 168-year-old global eye health company, publicly traded on NYSE/TSX (BLCO) as a subsidiary of Bausch Health, that designs, manufactures, and sells ophthalmic surgical devices, intraocular lenses, contact lenses, ophthalmic pharmaceuticals, and consumer eye health products to surgeons, hospitals, and consumers across approximately 100 countries.

Ownership category

akta.pro rank

Product category

Ophthalmic surgical devices and eye health products

NAICS

Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460), Optical Goods Retailers (45613)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Comprehensive Eye Exams & Vision Care (HLAKAKAA)

Keywords

• Ophthalmic surgical devices
• Intraocular lenses
• Contact lens solutions
• Ophthalmic pharmaceuticals
• Vitreoretinal surgery systems

Headquarters

HQ city

Montpellier

HQ country

France

HQ region

Europe

Offices17 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Surgical Devices and Instruments: Revenue from ophthalmic surgical devices including the Stellaris Elite platform, intraocular lenses (monofocal and premium), vitrectomy cutters, lasers, viscoelastics, and precision surgical instruments sold to hospitals and ophthalmic surgeons globally.
2. Contact Lenses and Lens Care Products: Contact lenses (daily, reusable, silicone hydrogel) and lens care solutions (multi-purpose solutions such as Biotrue) generating recurring revenue through consumer and professional channels. Biotrue holds estimated 55-65% brand value share in Brazil contact lens solution market.
3. Ophthalmic Pharmaceuticals: Prescription ophthalmic drugs including anti-inflammatory, antibiotic, and glaucoma medications for in-office and at-home treatment. Revenue from pharmaceutical products dispensed through eye care professionals.
4. Consumer Eye Health Products: Over-the-counter (OTC) products, eye vitamins and dietary supplements (PreserVision AREDS formulations), and consumer eye care products available in pharmacies and retail.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Bausch + Lomb designs, manufactures, and markets a comprehensive portfolio of eye health products spanning ophthalmic surgical devices (Stellaris Elite platform, vitrectomy cutters, intraocular lenses, femtosecond and excimer lasers, viscoelastics, surgical instruments), ophthalmic pharmaceuticals (Xiidra, anti-infectives, glaucoma therapies), contact lenses and lens care solutions (Biotrue), and consumer eye health products (PreserVision eye vitamins). The company sells through B2B enterprise sales channels to hospitals, ambulatory surgery centers, and ophthalmic surgeons globally, while also distributing consumer products through retail, pharmacy, and e-commerce.

Product overview

Bausch + Lomb operates as a leading global eye health company with three core segments: Vision Care (contact lenses, lens care products, OTC products, dietary supplements), Pharmaceuticals (ophthalmic drugs), and Surgical (devices, instruments, IOLs). The Surgical portfolio centers on the Stellaris Elite™ combined cataract and retina surgery platform, featuring Bi-Blade+™ vitrectomy cutters, Adaptive Fluidics technology, and comprehensive IOL offerings including enVista Envy™, LuxSmart™, LuxGood™, and LuxLife™ lenses with Pure Refractive Optics Technology. The IOL portfolio spans monofocal, toric, and premium presbyopia-correcting options with preloaded delivery systems. Supporting products include VICTUS® Femtosecond Laser, TECHNOLAS TENEO™ Excimer Laser, ANTERION® diagnostic imaging, ACE Diagnostic Platform, BLutein™ surgical dyes, Amvisc® and EYEFILL® viscoelastics, and Storz® Ophthalmic Instruments. Surgical planning tools include Toric Calculators, Per Procedure Tray Configurator, and eIFU Portal. Glaucoma treatment pipeline includes ELIOS System (implant-free MIGS) and BL 1107 neuroprotective therapy. Sustainability initiatives encompass ONE by ONE and Every Contact Counts recycling programs with TerraCycle partnership.

Differentiator

Problem solved

Functional benefit

Brands

• Stellaris Elite: Vision Enhancement System - combined platform for anterior and posterior segment surgery
• enVista
• LuxSmart
• LuxGood
• Bi-Blade+
• ACE Diagnostic Platform
• VICTUS Femtosecond Laser Platform
• Storz Ophthalmic Instruments
• Technolas Teneo
• ANTERION
• Synergetics
• Vitreocare
• ONE by ONE Recycling Program

Products and services

• Stellaris Elite Vision Enhancement System
• Stellaris Activate
• Bi-Blade+ Dual-Port Vitrectomy Cutter
• enVista Envy Full Range of Vision IOL
• LuxSmart Preloaded Intraocular Lens
• LuxGood Preloaded Intraocular Lens
• LuxLife Preloaded Intraocular Lens
• LuxSmart TORIC Preloaded Intraocular Lens
• enVista TORIC Intraocular Lens
• enVista TORIC SimplifEYE Intraocular Lens
• enVista Aspire Monofocal Intraocular Lens
• enVista Preloaded Intraocular Lens
• EyeCee One Preloaded Intraocular Lens
• Akreos AO Preloaded Intraocular Lens
• Akreos AO MICS Intraocular Lens
• IC-8 Intraocular Lens
• VICTUS Femtosecond Laser Platform
• TECHNOLAS TENEO 317 Model 2 Excimer Laser
• ANTERION Diagnostic Imaging Platform
• ACE Diagnostic Platform
• BLutein Dyes
• Vitreocare Intraocular Dyes
• Amvisc Viscoelastic
• Amvisc Plus Viscoelastic
• EYEFILL Viscoelastics
• OcuCoat Viscoelastic
• Storz Ophthalmic Instruments
• Retina Surgical Instruments
• Cataract Surgical Instruments
• Cornea Protect
• ELIOS System
• Biotrue Contact Lens Solution
• PreserVision AREDS3 Eye Vitamins

Quantifiable outcome

• 25% increase in flow rate and 62% reduction in cutter vibration with Bi-Blade+ vs prior model
• +6 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature13 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Monroe Community College and The Manufacturers Association of Central New YorkminorStrategic or Co-development Partner · 13 May 2026Two-year robotics-focused apprenticeship program launched at Rochester manufacturing campus. Includes 4,000 hours of on-the-job training covering PLC expertise and robotics maintenance. Participants are paid company employees and earn a journeyman card upon completion. Addresses growing demand for skilled technicians.
• City TherapeuticscoreStrategic or Co-development Partner · 1 January 2024RNAi partnership for retinal disease treatment worth up to $485 million. City Therapeutics uses novel cityRNA technology to develop treatments that can reach tissues beyond the liver. Bausch + Lomb will commercialize resulting therapies. City headquartered in Cambridge, MA with ~65 employees.
• Alfa Instruments s.r.l.coreChannel Partner/ Reseller/ Distributor · 1 September 2022Exclusive global distribution agreement (excluding Italy where Alfa is based) for Vitreocare intraocular dyes including Vitreo Lutein, Single Lutein Blue, Double Lutein Blue (ILM and ERM staining), Phaco Lutein, and Trypan Blue. Bausch + Lomb assumed all distribution and commercial activities starting H1 2023. Dyes use lutein, a natural blue light filter with antioxidant properties.
• Munich Surgical Imaging GmbH (MSI)coreStrategic or Co-development Partner · 30 August 2022Strategic partnership for digital visualization and image-guided surgical applications in ophthalmology. MSI is a wholly-owned subsidiary of Heidelberg Engineering and developed a new ophthalmology platform integrating high-speed SS-OCT. Bausch + Lomb combining MSI visualization with its surgical strengths in cataract, refractive and vitreoretinal space.
• SanoculiscoreStrategic or Co-development Partner · 28 July 2022Bausch + Lomb made an equity investment in Sanoculis and entered into exclusive European distribution agreement for MIMS (Minimally Invasive Micro-Surgery) procedure for glaucoma treatment. Addresses unmet needs in glaucoma with implant-free surgical solution.
• TerraCyclecoreStrategic or Co-development Partner · 1 January 2019ONE by ONE Recycling program developed in partnership with TerraCycle collects and recycles used contact lenses, eye care and lens care materials. US program collected 724,922 pounds since launch; Canadian program (Every Contact Counts) collected over 78,269 pounds since 2019. Materials are typically not accepted by municipal recycling facilities, making this partnership unique in the industry.
• Hull Institute of Learning and Simulation (HILS)minorStrategic or Co-development Partner · 1 January 2019Partnership with HILS at Hull and East Yorkshire Eye Hospital to provide simulation training for young ophthalmologists. Bausch + Lomb demonstrates Stellaris Vision Enhancement System functionality and educates surgeons. HILS has 10 workstations (4 fixed, 6 mobile) for wet lab training. The facility was expanded in 2020 with Bausch + Lomb support.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Alcon: Largest pure-play global eye-care company, directly competing across surgical (cataract, vitreoretinal, refractive), contact lenses, and ophthalmic pharmaceuticals. Most directly comparable surgical platform and IOL portfolio to Bausch + Lomb.
• Johnson & Johnson Vision: Operates within J&J MedTech, competing head-to-head with B+L in contact lenses (Acuvue), IOLs (TECNIS), and refractive surgery. Comparable global distribution and brand strength in eye care.
• CooperVision (CooperCompanies): Pure-play contact lens and lens care manufacturer; subject of reported Jana Partners activist interest. Directly competes with B+L's Biotrue and contact lens franchise in retail and professional channels.
• HOYA Corporation (Vision Care): Major IOL and eyeglass lens manufacturer; competes with B+L's LuxSmart, enVista, and LuxGood IOL portfolios and shares the Japan/Asia-Pacific ophthalmic surgical channel.

Broad incumbents

• Carl Zeiss Meditec: Established ophthalmic device and diagnostic player; competes with B+L's ANTERION and surgical microscopy, and offers a broader portfolio spanning ophthalmology and neurosurgery.

Emerging players

• STAAR Surgical: Specializes in ICL (implantable collamer lenses) for refractive surgery. Competes in the premium vision-correction segment adjacent to B+L's refractive and premium IOL offerings.
• Glaukos Corporation: Pioneer in MIGS devices for glaucoma. Directly competes with B+L's ELIOS System and Sanoculis MIMS partnership as both companies target the implant-free and minimally invasive glaucoma surgery market.
• Heidelberg Engineering: Specialized diagnostic imaging company for ophthalmology; parent of Munich Surgical Imaging GmbH (MSI), which is partnered with B+L for digital visualization. Comparable technology base in OCT and surgical imaging.
• EyePoint Pharmaceuticals: Specialty ophthalmic pharmaceutical company developing sustained-release treatments for retinal diseases and glaucoma. Comparable to B+L's ophthalmic pharmaceutical and BL 1107 neuroprotective franchise.
• Nicox SA: Ophthalmology-focused pharmaceutical company developing treatments for glaucoma and ocular surface diseases. Overlaps with B+L's ophthalmic pharma pipeline and consumer eye-health positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bauschsurgical
• LinkedInlinkedin.com/company/15159797
• Instagraminstagram.com/bauschlombsurgical

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bausch + Lomb